T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 1, 2004, Pages 138-145

  Garg, Amit K ^a   Strom, Eric A ^a   McNeese, Marsha D ^a   Buzdar, Aman U ^a   Hortobagyi, Gabriel N ^a   Kuerer, Henry M ^a   Perkins, George H ^a   Singletary, S Eva ^a   Hunt, Kelly K ^a   Sahin, Asyegul ^a   Schechter, Naomi ^a   Valero, Vicente ^a   Tucker, Susan L ^a   Buchholz, Thomas A ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Locoregional recurrence; Mastectomy; Neoadjuvant chemotherapy; Tamoxifen

Indexed keywords

CHEMOTHERAPY; CORRELATION METHODS; MEDICAL IMAGING; PATHOLOGY; PATIENT MONITORING; RADIOTHERAPY; SURGERY; TUMORS;

CANCER PATIENTS; EARLY-STAGE DISEASES; PATHOLOGIC INVOLVEMENT; PATHOLOGIC PREDICTORS;

ONCOLOGY;

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; PREDNISONE; TAMOXIFEN; VINCRISTINE;

ADULT; AGED; BREAST CANCER; CALCULATION; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DRUG USE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECURRENT CANCER; RETROSPECTIVE STUDY; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 16544389007     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.10.037     Document Type: Article

References (19)

1. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer An overview of the randomised trials. Lancet. 355:2000;1757-1770.
2. Overgaard M., Hansen P.S., Overgaard J., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 337:1997;949-955.
3. Overgaard M., Jensen M.B., Overgaard J., et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 353:1999;1641-1648.
4. Ragaz J., Jackson S.M., Le N., et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 337:1997;956-962.
5. Koscielny S., Tubiana M. The link between local recurrence and distant metastases in human breast cancer. Int J Radiat Oncol Biol Phys. 43:1999;11-24.
6. Harris J.R., Halpin-Murphy P., McNeese M., et al. Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 44:1999;989-990.
7. Recht A., Edge S.B., Solin L.J., et al. Postmastectomy radiotherapy Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 19:2001;1539-1569.
8. Fisher B., Brown A., Mamounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 15:1997;2483-2493.
9. Bonadonna G., Veronesi U., Brambilla C., et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 82:1990;1539-1545.
10. Buchholz T.A., Tucker S.L., Masullo L., et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 20:2002;17-23.
11. Lenert J.T., Vlastos G., Mirza N.Q., et al. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol. 6:1999;762-767.
12. Buzdar A.U., Singletary S.E., Theriault R.L., et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 17:1999;3412-3417.
13. Buzdar A.U., Singletary S.E., Booser D.J., et al. Combined modality treatment of stage III and inflammatory breast cancer M. D. Anderson Cancer Center experience. Surg Oncol Clin North Am. 4:1995;715-734.
14. Hortobagyi G.N., Ames F.C., Buzdar A.U., et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 62:1988;2507-2516.
15. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;547-581.
16. Kuerer H.M., Sahin A.A., Hunt K.K., et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 230:1999;72-78.
17. Rouzier R., Extra J.M., Klijanienko J., et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 20:2002;1304-1310.
18. Katz A., Strom E.A., Buchholz T.A., et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy Implications for postoperative irradiation. J Clin Oncol. 18:2000;2817-2827.
19. Katz A., Strom E.A., Buchholz T.A., et al. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys. 50:2001;735-742.